Ocular Therapeutix Engages in Key Scientific Conferences Ahead

Ocular Therapeutix Engages in Key Scientific Conferences Ahead

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a prominent biopharmaceutical company focused on transforming the retina therapy landscape, recently announced its participation in several important scientific conferences scheduled in the near future.

Highlighting the OIS Retina Innovation Summit

The 8th Annual OIS Retina Innovation Summit, set to take place in Long Beach, will feature Ocular Therapeutix as a key participant. This summit aims to spotlight innovations in drug delivery, an essential focus for the company.

Company Presentations

Sanjay Nayak, MBBS, PhD, who serves as the Chief Strategy Officer, will lead a presentation during the session dedicated to drug delivery. This engaging session is scheduled for Tuesday, providing valuable insights into the latest advancements in retinal therapies.

Panel Discussion

Also participating will be Chief Development Officer Peter K. Kaiser, MD. He will partake in the panel titled "Spotlight on Drug Delivery," shedding light on Ocular Therapeutix's commitment to improving treatment outcomes for retinal conditions.

Key Insights from the ASRS Annual Meeting

Continuing its engagement in key scientific dialogues, Ocular Therapeutix will also contribute to the 43rd Annual Scientific Meeting of the American Society of Retinal Specialists. This event is a platform for sharing groundbreaking research and developments in retinal treatments.

Scientific Presentations

Katherine Talcott, MD, will present a significant study on the assessment of retinal leakage in diabetic retinopathy, titled "Longitudinal Quantitative Ultra-Widefield Retinal Leakage Assessment in Diabetic Retinopathy Following a Single Axitinib Hydrogel (OTX-TKI) in the HELIOS Trial." Scheduled for Thursday, this presentation aims to uncover vital metrics that can influence ongoing treatment strategies.

Poster Presentations on Diabetic Retinopathy

Further, Devesh Kumar, MD, will present his research titled "Macular Volumetric Fluid Outcomes Following Treatment with Intravitreal Axitinib Hydrogel (OTX-TKI) in Non-Proliferative Diabetic Retinopathy" during the poster session. This poster session allows for insightful discussions and networking on advancements in the area.

Women in Ophthalmology Conference Participation

Ocular Therapeutix will also be at the Women in Ophthalmology Conference in Amelia Island, where it will present its research. This forum encourages the exchange of ideas and the sharing of female leadership in the field.

Posters on Treatment Efficacy

Diana Do, MD, will showcase her findings on "Macular Fluid Volume and Retinal Vascular Leakage Analysis Following a Single Axitinib Intravitreal Hydrogel in Diabetic Retinopathy." The dual poster presentations are designed to reach a broad audience, and they reflect Ocular's dedication to understanding and improving retinal health.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. stands at the forefront of biopharmaceutical innovation, emphasizing the enhancement of the retinal experience through its research and development initiatives. Among its key products, AXPAXLI™ (OTX-TKI) is currently in Phase 3 clinical trials aimed at combating wet age-related macular degeneration (wet AMD). This investigational treatment, based on a unique bioresorbable hydrogel formulation, represents a significant potential advancement in the management of retinal diseases.

Moreover, the company’s pipeline features DEXTENZA, an FDA-approved corticosteroid used in treating ocular inflammation following surgery, exemplifying its focus on addressing diverse ocular needs. Their investigational candidate, OTX-TIC, is also showing promise, being evaluated in a Phase 2 clinical trial for open-angle glaucoma or ocular hypertension.

Ocular Therapeutix is dedicated to reshaping the landscape of ocular therapeutics, ensuring patients receive breakthrough solutions that enhance their quality of life.

Contact Information

For further inquiries, Ocular Therapeutix, Inc. can be reached through their Vice President of Investor Relations, Bill Slattery, at bslattery@ocutx.com.

Frequently Asked Questions

What is Ocular Therapeutix known for?

Ocular Therapeutix, Inc. is known for developing innovative biopharmaceutical therapies aimed at treating retinal diseases and enhancing ocular health.

What conferences is Ocular Therapeutix participating in?

Ocular Therapeutix is participating in the OIS Retina Innovation Summit and the American Society of Retinal Specialists Annual Meeting, among others.

What is AXPAXLI?

AXPAXLI™ (also OTX-TKI) is Ocular Therapeutix's investigational drug for retinal diseases, currently undergoing Phase 3 trials for wet AMD.

How does DEXTENZA work?

DEXTENZA is an FDA-approved corticosteroid that helps manage ocular inflammation and pain following ophthalmic surgery.

Who can be contacted for investor inquiries?

Bill Slattery, the Vice President of Investor Relations at Ocular Therapeutix, can be contacted for inquiries related to investments.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.